Galectin Therapeutics Inc. (GALT)

[buckysherm]

Ten X would NOT give up their preferred shares and go into common without either a big partnership or a buyout. I’m all in. Didn’t think anyone was listening; glad you’re aboard.

[stock_observer_77]

Quiet here

No discussion about the PR?

[buckysherm]

Up 40 cents on less than 40 K shares ??

[stock_observer_77]

No idea. I liked the news though.

[buckysherm]

I’m expecting this to drag on for months, cause I will have to sell by then. My luck could only be worse if I were hit by an asteroid.

[stock_observer_77]

Still holding shares waiting for BO

[buckysherm]

B shares are being converted, this could be in prep for partnership or BO !

[mikeslife]

From Yahoo Finance:
Latest analyst ratings for GALT:

Fidelity Equity Summary Score: Very Bullish (10) as of 1/12/2019
Columbine Capital Services Inc.: Outperform as of 12/28/2018
Roth Capital Partners: Buy as of 3/02/2018
Thomson Reuters/Verus: Buy as of 1/07/2019
ValuEngine: Outperform as of 1/10/2019
Zacks Investment Research, Inc: Strong Buy as of 1/11/2019
H.C. Wainwright: Buy $12 price target as of 12/19/2018

[buckysherm]

GALT is about to drop precipitously, because I am the most frequent poster on this board. Short the stock !!!!!!

[buckysherm]

Up 10% on 17 K shares ?

[mikeslife]

On Stocktwits many of the posters are delusional and post from 6 am till midnight.

[buckysherm]

In here and Stock Twits, people are so quick to take little little things and turn them into signs of a buy out. It is a possibility, but I see no real sign yet.

[buckysherm]

More updates means that he will continue to provide articles in 2019

[mikeslife]

Link to go along with my last post
https://liverline.com/in-case-you-missed-it-top-liver-related-news-of-the-week-ae7d749d07a1

[mikeslife]

FYI:post from GALT board on Yahoo finance

SpaceFlower2 hours ago
Could this be.. GALT CEO signaling to the market that a deal is near? They don't typically post about other industry licensing deals. Posted to Facebook just an hour ago:

"New collaborations in NASH news? Check out our second In Case You Missed It blog post on the Liver Line to catch up on recent, industry news."

[mikeslife]

https://www.streetwisereports.com/article/2018/12/24/therapeutics-developer-secures-patents-continues-phase-3-trial-planning.html

[jimmy667]

Maybe the BO is starting to happen now. On the open market up 13% in a down market day and has been paused for volatility this morning.

[buckysherm]

Sorry, wrong board.

[buckysherm]

Actually 5 bullish SA articles in last 8 days. 5 different authors.

[buckysherm]

This SA article disagrees. Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise $CNAT https://seekingalpha.com/article/4227368

[Amatuer17]

CNAT trial results were bad - they tanked

[buckysherm]

Could this also be an indication that CNAT (funded by Novartis) May be out in the cold ?

[Amatuer17]

Look at GLMD - the phase 3 trial will start by end of Q2-2019 - that is 8 months from now and they have money.
How much GALT take to start? They have limited money.

[mikeslife]

I couldn't agree more. Keep your fingers crossed.

[1hb]

B.O. imo IF IF we get up two points in a day as while we know liver product is great no big news there till next phase clinical 2019. We know B.O. or partnership has been point blank stated...time is closing in on that...

[microcapbiotech]

going UP on down biotech days.

[1hb]

I agree, caught my eye yesterday...note last two five minute volume bars and price with msrket falling hard into close...today relentless up and now look at wide swings and bid ask was 10 cents !! spread.....twenty minutes of wide swings also some gaps up even INTRADAY !!!! MUST

[microcapbiotech]

There's something happening here,
BUY Now before the news comes out.

[Amatuer17]

Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH

Does this mean that 2 BP are put of acquisition option for GALT - GLMD - MDGL?

Does it also mean that GILD and others will go for these acquisition faster?

https://finance.yahoo.com/news/pfizer-announces-clinical-development-agreement-061500415.html

[thefamilyman]

New Form 4: A Director bought 2000 shares at $6.0999 per share.

[thefamilyman]

New prospectus out:

It covers the conversion of existing preferred shares and the exercise of existing warrants which would result in over $20 million in funding for our company.

[buckysherm]

GRMD02 improves Keytruda effectiveness by 4 times !
GALT published Keytruda head & neck 16% ORR, Complete response 5%, with GR-MD-02 67% and 33%.

[buckysherm]

https://www.keytruda.com/head-and-neck-cancer/keytruda-clinical-trials/

[Chess Master]

GALT UPGRADED! They got one from Seaport and one from HC Wainwright
https://sgsecurities.bluematrix.com/sellside/EmailDocViewer?encrypt=428e4606-b6cb-4b5f-bd67-77ff47073687&mime=pdf&co=ghsecurities&id=[e-mail]&source=mail

[Chess Master]

Looks like Feuerstein taken to woodshed in article
https://emerginggrowth.com/galectin-therapeutics-inc-nasdaq-galt-most-feared-biotech-analyst-losing-relevance-as-investors-crave-substance-over-cyber-bullying/

[Amatuer17]

Interesting article

https://msmoneymoves.com/2018/09/20/market-not-grasping-the-magnitude-of-galt-phase1b-keytruda-combo-study/

[mikeslife]

I hate to be "Debbie Downer" and I realize the market is open for a couple more hours but I would have thought today's news would have a greater increase in stock price than we have seen today.

[buckysherm]

Galt patients story :
http://markanehornibrook.blogspot.com/?m=1

[Coolec78]

Take A look 33% keytruba alone, 50% with GALT. That's almost 50% better response rate.

[buckysherm]

That’s right ! 17% better on hard to treat patients than Keytruda alone on first-time patients. Plus Fewersteins friends shorting every day. How could there be much of a pop ? There could be higher volume, a la Viking.

[Coolec78]

But still it is 17%more than keytruba alone plus 2 patients stabilized makes over 60. Not bad for hard to treat patients.
Plus this is only 1b trial about safety. There is some room to play with dosage and length of the therapy.

[Amatuer17]

The overall impact % is 50 which is much lower than what market expected.

Also co did not give the C3 results clearly

[buckysherm]

After that good news this morning, we might be LOWER in the first hour ?? How odd.

[Amatuer17]

Ketruda is PD-1 and Yervoy is CTLA and Yervoy is found to be much less efficacious than Ketruda and Opdivo both of which are PD-1. So it made sense to go with Ketruda

[thefamilyman]

Thanks Amateur. I found it in the presentation below.

http://galectintherapeutics.com/wp-content/uploads/2018/07/2018-Galectin-Presentation-Immunooncology-FINAL.pdf

I find it interesting that there were only three patients in Cohort 2 with Yervoy at the 2mg dose and of those three; 2 patients had a Partial Response and the other patient had a Complete Response but the trial was terminated in favor of starting up with Keytruda. I wish it had continued. It would be interesting to see how the two combinations compared head to head (GR-MD-02/Yervoy vs GR-MD-02/Keytruda).

Sounds like there might have been the potential for an interesting bidding war. Maybe there still is...

[Amatuer17]

The Yervoy trial was stopped as they moved to Ketruda

[thefamilyman]

Michael Golden has this comment at the end of the article.
“The cancer trial is being run in combination with KEYTRUDA, not Yervoy, how could you make such a major error and expect to be taken seriously?”

I believe that Providence Portland is currently running combo trials on both Keytruda and Yervoy. We are expecting the results of Cohort 3 with Keytruda shortly. I do not recall when we are expecting to hear results on Yervoy. I tried to reply to his comment but it would not let me. If you can, please reply to his comment.

[mikeslife]

FYI:
https://emerginggrowth.com/galectin-therapeutics-nasdaq-galt-were-not-dealing-with-apple-juice-here/

[Amatuer17]

He writes in depth but acts like pumper.
His says the cohort 3 results are due this week but no one knows - it is possible but one cannot say.

I am keeping my fingers crossed - if C3 really shows results as everyone is predicting, we will fly.

[Chess Master]

Anyone see this blog posting - very in depth
https://seekingalpha.com/instablog/19785151-michael-sheikh/5213282-handicapping-upcoming-providence-cancer-data-melanoma

might be moving the market